belimumab

Ligand id: 6887

Name: belimumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: belimumab

References
1. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L et al.. (2003)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
Arthritis Rheum.48 (11): 3253-65. [PMID:14613291]
2. Dörner T. (2006)
Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
J Rheumatol Suppl77: 3-11. [PMID:16652439]
3. Lutalo PM, D'Cruz DP. (2014)
Update on belimumab for the management of systemic lupus erythematosus.
Expert Opin Biol Ther14 (11): 1701-8. [PMID:25303323]
4. Sabahi R, Anolik JH. (2006)
B-cell-targeted therapy for systemic lupus erythematosus.
Drugs66 (15): 1933-48. [PMID:17100405]
5. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H et al.. (1999)
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.
J. Exp. Med.189 (11): 1747-56. [PMID:10359578]